8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2022

Commission File Number: 0-24260

Amedisys, Inc.

(Exact name of registrant as specified in charter)

Delaware	11-3131700
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	AMED	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SECTION 7 - REGULATION FD

Item 7.01. Regulation FD Disclosure.

On June 9, 2022, Amedisys, Inc. (the “Company”) issued a press release announcing that it has released its first Environmental, Social and Governance (ESG) Report for 2021, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

Also on June 9, 2022, the Company issued a press release announcing that its wholly-owned subsidiary, Contessa Health, Inc., entered into a partnership with Baylor Scott & White Health to create new alternative care models to extend comprehensive, coordinated medical care to patients’ homes, a copy of which is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release dated June 9, 2022 (announcing the release of the Company’s inaugural Environmental, Social and Governance (ESG) Report)
99.2	Press Release dated June 9, 2022 (announcing Contessa’s partnership with Baylor Scott & White Health)
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.
By:	/s/ Christopher T. Gerard
Christopher T. Gerard
President and Chief Executive Officer
DATE: June 9, 2022

EX-99.1

Exhibit 99.1

Amedisys Releases Inaugural Environmental, Social and Governance (ESG) Report

BATON ROUGE, La., June 9, 2022 –Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, has released its first Environmental, Social and Governance (ESG) Report for the year 2021, detailing actions, achievements and goals in each critical area.

“We are in the early stages of mapping our progress with the goal of being a good corporate citizen and to act responsibly in the way we treat our patients, our employees, our communities and the environment that we all share,” stated President and CEO Chris Gerard. “We wholly embrace our responsibility to advance social and environmental causes for the betterment of our communities and commit to operating with the highest standards of compliance and ethics.”

Amedisys participated in an ESG materiality assessment with independent consultants to identify key topics and areas of opportunity to begin tracking and reporting on key performance indicators for each. A newly formed ESG committee, comprised of executives and senior management, will develop, implement and monitor these initiatives and policies.

Highlights from the report include Amedisys’ commitment to:

+ A strong system of independent governance to ensure the Company meets the high standards expected of a leading healthcare company

+ Create an open and inclusive place to work, with comprehensive benefits, personal and professional development and high clinical standards

+ Ensure a diverse and inclusive workplace free of discrimination and to build capacity and competency to manage it

+ Continue outperforming the industry in quality of patient care in all lines of business

+ Support our employees and patients through the Amedisys Foundation

+ Quantify our environmental impact to develop meaningful strategies to help combat climate change

+ Achieve net-zero GHG emissions from our operations no later than 2050

The report has been informed by the guidance of the Value Reporting Foundation’s Sustainability Accounting Standards Board (SASB) and is accessible on Amedisys’ investors site.

Contact:
Nick Muscato	Kendra Kimmons
Amedisys, Inc.	Amedisys, Inc.

Investor Relations	Media Relations
615.928.5452	225.299.3720
nick.muscato@amedisys.com	Kendra.kimmons@amedisys.com

About Amedisys:

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility (“SNF”) care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees, in 549 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year, performing more than 11.5 million visits annually. For more information about the Company, please visit: www.amedisys.com.

Forward Looking Statements:

This press release contains information regarding our plans, goals, commitments and other “forward-looking statements” as that phrase is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties, and actual results may differ materially from those described therein, including any failure to meet stated goals and commitments in our ESG framework. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; the impact of current and proposed federal, state and local vaccine mandates, including potential staff shortages; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in Medicare and other medical payment levels; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; competition in the healthcare industry; changes in the case mix of patients and payment methodologies; changes in estimates and judgments associated with critical accounting policies; our ability to maintain or establish new patient referral sources; our ability to consistently provide high-quality care; our ability to attract and retain qualified personnel; our ability to keep our patients and employees safe; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest; our ability to integrate, manage and keep our information systems secure; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

EX-99.2

Exhibit 99.2

FOR IMMEDIATE RELEASE	Contacts:
June 9, 2022	Dana Schroering, Contessa (502) 727-0193 dschroering@contessahealth.com Julie Smith, Baylor Scott & White Health (940) 765-7560 Julie.Smith@BSWHealth.org

Baylor Scott & White Health and Contessa Announce Partnership to Create New Model of At-Home Care for Patients

Partnership will create a continuum of at-home care that encourages patient choice, reduces costs and improves outcomes

Dallas, Texas; and Nashville, Tenn. – June 9, 2022 – Baylor Scott & White Health, the largest not-for-profit health system in Texas, and Contessa, an Amedisys company (NASDAQ: AMED) and the nation’s leading high-acuity home care provider, announce a partnership to provide patients with a high-quality continuum of care in the home.

The continuum of care will include new alternative care models to extend comprehensive, coordinated medical care to patients’ homes, including hospital-level care, palliative or supportive care, and skilled nursing care. Baylor Scott & White will begin communicating the new programs to eligible patients in 2023.

“We are dedicated to developing and delivering new, convenient options for our patients, offering high quality care when and where they want it,” said Pete McCanna, chief executive officer at Baylor Scott & White. “These innovative at-home solutions will empower those we serve, enhancing the recovery process and improving outcomes.”

Once the programs are launched, eligible patients will be offered an alternative to conventional inpatient hospitalization as well as other services, including skilled nursing care at home and options for additional support and assistance for seriously ill patients, their families and caregivers. Data shows that Contessa’s model reduces readmission rates by 44%, decreases the length of hospital stays by 35% and has a patient satisfaction rate of more than 90%.

“We are thrilled to partner with Baylor Scott & White to offer greater options to patients, improving their experience,” said Travis Messina, chief executive officer at Contessa. “Baylor Scott & White has a century-long reputation for providing high-quality care in the communities it serves, and we are eager to work collaboratively to soon provide hospital-level care to patients within the comfort and safety of their homes.”

###

About Baylor Scott & White Health:

As the largest not-for-profit health system in the state of Texas, Baylor Scott & White promotes the health and well-being of every individual, family and community it serves. It is committed to making quality care more accessible, convenient and affordable through its integrated delivery network, which includes the Baylor Scott & White Health Plan, Baylor Scott & White Research Institute, the Baylor Scott & White Quality Alliance and its leading digital health platform – MyBSWHealth. Through 51 hospitals and more than 1,100 access points, including flagship academic medical centers in Dallas, Fort Worth and Temple, the system offers the full continuum of care, from primary to award-winning specialty care. Founded as a Christian ministry of healing more than a century ago, Baylor Scott & White today serves more than three million Texans. For more information, visit BSWHealth.com

About Contessa:

Based in Nashville, Contessa is the leader and pioneer of Home Recovery Care, a risk-based model that combines all the essential elements of inpatient hospital care in the comfort of patients’ homes. Founded in 2015, Contessa utilizes Care Convergence – a proprietary technology platform – to power the seamless delivery of Home Recovery Care that is safe, affordable and improves patient outcomes. Contessa’s turnkey solution provides upfront savings to health plans, enables health systems to reinvent their care delivery model and helps physicians deliver a better experience for patients. For more information, visit contessahealth.com or follow us at @contessahealth.

About Amedisys:

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility (“SNF”) care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees, in 549 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year, performing more than 11.5 million visits annually. For more information about the Company, please visit: www.amedisys.com.

Forward-Looking Statements:

When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and

uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; the impact of current and proposed federal, state and local vaccine mandates, including potential staff shortages; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in Medicare and other medical payment levels; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; competition in the healthcare industry; changes in the case mix of patients and payment methodologies; changes in estimates and judgments associated with critical accounting policies; our ability to maintain or establish new patient referral sources; our ability to consistently provide high-quality care; our ability to attract and retain qualified personnel; our ability to keep our patients and employees safe; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest; our ability to integrate, manage and keep our information systems secure; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

XML

Document and Entity Information	Jun. 09, 2022
Cover [Abstract]
Entity Registrant Name	AMEDISYS INC
Amendment Flag	false
Entity Central Index Key	0000896262
Document Type	8-K
Document Period End Date	Jun. 09, 2022
Entity File Number	0-24260
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	11-3131700
Entity Address, Address Line One	3854 American Way
Entity Address, Address Line Two	Suite A
Entity Address, City or Town	Baton Rouge
Entity Address, State or Province	LA
Entity Address, Postal Zip Code	70816
City Area Code	(225)
Local Phone Number	292-2031
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	AMED
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false